Vanda Pharmaceutical (VNDA) 10.81 $VNDA
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 10:00 a.m. Eastern Time.
VNDA: 10.81 (-0.17)
Ulta Salon, FEI and Vanda Pharma rise while Terex slumps
AP - Fri May 27, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
VRX: 24.14 (-1.34), VNDA: 10.81 (-0.17), GOOGL: 733.19 (-9.33), TEX: 21.10 (-0.03), PANW: 131.26 (-3.58), GOOG: 719.41 (-9.17), VRX.TO: 30.80 (-1.39), APC: 53.00 (-1.48), FEIC: 106.75 (-0.48)
Vanda Pharmaceuticals Rises 9.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 27, 3:09PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $9.85 to a high of $10.49. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $9.90 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 10.81 (-0.17)
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
PR Newswire - Thu May 26, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to describe the effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) placebo-controlled clinical study which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The study data submitted in the sNDA came from the REPRIEVE study in which Vanda previously reported 79.6% of patients treated with Fanapt® remained relapse free compared to 36.6% for placebo-treated patients.
VNDA: 10.81 (-0.17)
Vanda reports 1Q loss
Automated Insights - Wed May 04, 4:07PM CDT
WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $12.4 million in its first quarter.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 14, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016, after the market closes.
VNDA: 10.81 (-0.17)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 6.65 (-0.50), VNDA: 10.81 (-0.17), LPCN: 8.16 (-0.94), CHMA: 2.91 (-0.23)
Vanda Pharmaceuticals Down 35.9% Since SmarTrend Downtrend Call (VNDA)
Comtex SmarTrend(R) - Wed Mar 30, 12:22AM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 6 months, Vanda Pharmaceuticals has returned 35.86% as of today's recent price of $7.78.
VNDA: 10.81 (-0.17)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 9.88 (-0.49), VNDA: 10.81 (-0.17), GNCA: 3.94 (-0.28), DRRX: 1.29 (-0.03)
Vanda Pharmaceuticals Has Returned 35.3% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Mar 22, 1:00PM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 6 months, Vanda Pharmaceuticals has returned 35.28% as of today's recent price of $7.85.
VNDA: 10.81 (-0.17)
Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology
ACCESSWIRE - Tue Mar 08, 8:29AM CST
REDONDO BEACH, CA / ACCESSWIRE / March 8, 2016 / Right now there is hypochlorous acid, or HOCl, on the immunological front lines in the bodies of people fighting infections, doing its job as an inorganic bactericidal compound of the innate immune system to destroy a wide spectrum of pathogens. Although still not used as a pharmaceutical drug, the important role of hypochlorous acid in biology is only recently emerging, in addition to its well-documented germicidal properties. For example, research by Serhan Sakarya, MD, et al. shows that HOCl in stable form is an ideal wound care solution with a powerful and rapid killing effect on different types of microorganisms, biofilms and microbicidal effect within the biofilm.
AQXP: 7.35 (-0.04), VNDA: 10.81 (-0.17), VTAE: 10.19 (+0.07), OCLS: 0.96 (unch)
Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results
PR Newswire - Wed Feb 10, 3:01PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2015.
VNDA: 10.81 (-0.17)
30.5% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Mon Feb 08, 11:45AM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 30.46% as of today's recent price of $8.44.
VNDA: 10.81 (-0.17)
Shares of VNDA Down 30.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 08, 11:20AM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 30.46% as of today's recent price of $8.44.
VNDA: 10.81 (-0.17)
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 10.81 (-0.17), MRK: 56.81 (-0.37), GSK: 40.93 (-1.13)
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
PR Newswire - Mon Feb 01, 3:30PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 2, 2016 in New York City.
VNDA: 10.81 (-0.17)
Downtrend Call Working As Vanda Pharmaceuticals Stock Falls 29.7% (VNDA)
Comtex SmarTrend(R) - Fri Jan 29, 6:10PM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 29.68% as of today's recent price of $8.53.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals Shares Down 28.2% Since SmarTrend's Sell Call (VNDA)
Comtex SmarTrend(R) - Fri Jan 22, 4:33PM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 28.19% as of today's recent price of $8.71.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016
PR Newswire - Fri Jan 22, 8:20AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10, 2016, after the market closes.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 10:00 a.m. Eastern Time.
VNDA: 10.81 (-0.17)
Ulta Salon, FEI and Vanda Pharma rise while Terex slumps
AP - Fri May 27, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
VRX: 24.14 (-1.34), VNDA: 10.81 (-0.17), GOOGL: 733.19 (-9.33), TEX: 21.10 (-0.03), PANW: 131.26 (-3.58), GOOG: 719.41 (-9.17), VRX.TO: 30.80 (-1.39), APC: 53.00 (-1.48), FEIC: 106.75 (-0.48)
Vanda Pharmaceuticals Rises 9.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 27, 3:09PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $9.85 to a high of $10.49. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $9.90 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 10.81 (-0.17)
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
PR Newswire - Thu May 26, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to describe the effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) placebo-controlled clinical study which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The study data submitted in the sNDA came from the REPRIEVE study in which Vanda previously reported 79.6% of patients treated with Fanapt® remained relapse free compared to 36.6% for placebo-treated patients.
VNDA: 10.81 (-0.17)
Vanda reports 1Q loss
Automated Insights - Wed May 04, 4:07PM CDT
WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $12.4 million in its first quarter.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 14, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016, after the market closes.
VNDA: 10.81 (-0.17)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 6.65 (-0.50), VNDA: 10.81 (-0.17), LPCN: 8.16 (-0.94), CHMA: 2.91 (-0.23)
Vanda Pharmaceuticals Down 35.9% Since SmarTrend Downtrend Call (VNDA)
Comtex SmarTrend(R) - Wed Mar 30, 12:22AM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 6 months, Vanda Pharmaceuticals has returned 35.86% as of today's recent price of $7.78.
VNDA: 10.81 (-0.17)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 9.88 (-0.49), VNDA: 10.81 (-0.17), GNCA: 3.94 (-0.28), DRRX: 1.29 (-0.03)
Vanda Pharmaceuticals Has Returned 35.3% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Mar 22, 1:00PM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 6 months, Vanda Pharmaceuticals has returned 35.28% as of today's recent price of $7.85.
VNDA: 10.81 (-0.17)
Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology
ACCESSWIRE - Tue Mar 08, 8:29AM CST
REDONDO BEACH, CA / ACCESSWIRE / March 8, 2016 / Right now there is hypochlorous acid, or HOCl, on the immunological front lines in the bodies of people fighting infections, doing its job as an inorganic bactericidal compound of the innate immune system to destroy a wide spectrum of pathogens. Although still not used as a pharmaceutical drug, the important role of hypochlorous acid in biology is only recently emerging, in addition to its well-documented germicidal properties. For example, research by Serhan Sakarya, MD, et al. shows that HOCl in stable form is an ideal wound care solution with a powerful and rapid killing effect on different types of microorganisms, biofilms and microbicidal effect within the biofilm.
AQXP: 7.35 (-0.04), VNDA: 10.81 (-0.17), VTAE: 10.19 (+0.07), OCLS: 0.96 (unch)
Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results
PR Newswire - Wed Feb 10, 3:01PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2015.
VNDA: 10.81 (-0.17)
30.5% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Mon Feb 08, 11:45AM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 30.46% as of today's recent price of $8.44.
VNDA: 10.81 (-0.17)
Shares of VNDA Down 30.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 08, 11:20AM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 30.46% as of today's recent price of $8.44.
VNDA: 10.81 (-0.17)
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 10.81 (-0.17), MRK: 56.81 (-0.37), GSK: 40.93 (-1.13)
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
PR Newswire - Mon Feb 01, 3:30PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 2, 2016 in New York City.
VNDA: 10.81 (-0.17)
Downtrend Call Working As Vanda Pharmaceuticals Stock Falls 29.7% (VNDA)
Comtex SmarTrend(R) - Fri Jan 29, 6:10PM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 29.68% as of today's recent price of $8.53.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals Shares Down 28.2% Since SmarTrend's Sell Call (VNDA)
Comtex SmarTrend(R) - Fri Jan 22, 4:33PM CST
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on September 28th, 2015 at $12.13. In approximately 4 months, Vanda Pharmaceuticals has returned 28.19% as of today's recent price of $8.71.
VNDA: 10.81 (-0.17)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016
PR Newswire - Fri Jan 22, 8:20AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10, 2016, after the market closes.
VNDA: 10.81 (-0.17)
